keyword
MENU ▼
Read by QxMD icon Read
search

Tace

keyword
https://www.readbyqxmd.com/read/28643457/eradication-of-hepatitis-c-virus-profoundly-prolongs-survival-in-hepatocellular-carcinoma-patients-receiving-transarterial-chemoembolization
#1
Wei Teng, Yi-Chung Hsieh, Kar-Wai Lui, Wei-Ting Chen, Chien-Fu Hung, Chien-Hao Huang, Yi-Cheng Chen, Wen-Juei Jeng, Chen-Chun Lin, Chun-Yen Lin, Shi-Ming Lin, I-Shyan Sheen
Adjuvant pegylated interferon plus ribavirin treatment (PegIFN/RBV) reduces recurrence and prolongs survival in early stage hepatocellular carcinoma (HCC) patients with chronic hepatitis C (CHC) infection receiving resection or ablation. However, the impact of antiviral therapy in intermediate and advanced stage of CHC-HCC patients is uncertain. This study aimed to investigate the impact PegIFN/RBV treatment on recurrence free interval and survival in HCC patients receiving transarterial chemoembolization (TACE) METHODS: From 2010 to 2013, 274 CHC patients from a 1073-patients based cohort composed of freshly diagnosed HCC and receiving TACE treatment the Chang Gung Memorial Hospital, Linkou Medical Center were recruited...
June 22, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/28643305/-interventional-therapy-of-colorectal-liver-metastasis
#2
Qi Zhang, Gaojun Teng
Colorectal liver metastasis (CRLM) is one of the most difficult and key points in the treatment of colorectal cancer. Approximately 50% to 60% of patients diagnosed as colorectal cancer develops metastasis, and 80% to 90% of CRLM is unresectable. Surgical resection is the first-line treatment for CRLM, while it is only suitable for about 15% patients. Systemic chemotherapy can prolong the survival of CRLM patients, however, a part of CRLM patients are resistant to chemotherapy. With the development of technology and the update of clinical evidence, individual therapy with target drugs and multidisciplinary treatment (MDT) have became a tendency, and minimally invasive interventional therapy has gained more acceptance in the MDT mode of the treatment for CRLM...
June 25, 2017: Zhonghua Wei Chang Wai Ke za Zhi, Chinese Journal of Gastrointestinal Surgery
https://www.readbyqxmd.com/read/28640364/a-phase-2-study-of-the-efficacy-and-biomarker-on-the-combination-of-transarterial-chemoembolization-and-axitinib-in-the-treatment-of-inoperable-hepatocellular-carcinoma
#3
Stephen L Chan, Winnie Yeo, Frankie Mo, Anthony W H Chan, Jane Koh, Leung Li, Edwin P Hui, Charing C N Chong, Paul B S Lai, Tony S K Mok, Simon C H Yu
BACKGROUND: A surge of vascular endothelial growth factor (VEGF) after transarterial chemoembolization (TACE) may contribute to tumor progression. Axitinib is a potent antiangiogenic agent with main activity against VEGF receptors 1 to 3. To the authors' knowledge, its role in combination with TACE for the treatment of patients with inoperable hepatocellular carcinoma (HCC) is unclear. METHODS: A phase 2 clinical trial (ClinicalTrials.gov identifier NCT01352728) was conducted to evaluate the combination treatment...
June 22, 2017: Cancer
https://www.readbyqxmd.com/read/28634515/transarterial-chemoembolization-using-40-%C3%A2%C2%B5m-drug-eluting-beads-for-hepatocellular-carcinoma
#4
Giorgio Greco, Tommaso Cascella, Antonio Facciorusso, Roberto Nani, Rodolfo Lanocita, Carlo Morosi, Marta Vaiani, Giuseppina Calareso, Francesca G Greco, Antonio Ragnanese, Marco A Bongini, Alfonso V Marchianò, Vincenzo Mazzaferro, Carlo Spreafico
AIM: To assess the safety and efficacy of transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) using a new generation of 40 μm drug eluting beads in patients not eligible for curative treatment. METHODS: Drug eluting bead TACE (DEB-TACE) using a new generation of microspheres (embozene tandem, 40 μm) preloaded with 100 mg of doxorubicin was performed on 48 early or intermediate HCC patients with compensated cirrhosis. Response to therapy was assessed with Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST (mRECIST) guidelines applied to computed tomography or magnetic resonance imaging...
May 28, 2017: World Journal of Radiology
https://www.readbyqxmd.com/read/28631359/management-of-pediatric-hepatocellular-carcinoma-a-multimodal-approach
#5
Mira A Kohorst, Deepti M Warad, Jane M Matsumoto, Julie K Heimbach, Mounif El-Youssef, Carola A S Arndt, Vilmarie Rodriguez, Amulya A Nageswara Rao
HCC is rare in the pediatric population, but is the second most common liver malignancy in children. Survival rates for primary unresectable HCC have been dismal. The objective of this study was to describe our experience with a multimodal approach for the management of unresectable HCC in two adolescent patients and to review the literature. Both patients are currently alive with no recurrence at 51 and 29 months post-transplant. Multimodality treatment involving chemotherapy with doxorubicin, cisplatin, and sorafenib; TACE; timely liver transplantation; and post-transplant therapy with sorafenib and mTOR inhibitors may help improve outcomes and prolong survival in pediatric patients with unresectable HCC...
June 20, 2017: Pediatric Transplantation
https://www.readbyqxmd.com/read/28629564/computed-tomography-perfusion-imaging-for-monitoring-transarterial-chemoembolization-of-hepatocellular-carcinoma
#6
Herman P Marquez, Amar Karalli, Holger Haubenreisser, Rishi P Mathew, Hatem Alkadhi, Torkel B Brismar, Thomas Henzler, Michael A Fischer
PURPOSE: To prospectively monitor changes in tumor perfusion of hepatocellular carcinoma (HCC) in response to doxorubicin-eluted bead based transarterial chemoembolization (DEB-TACE) using perfusion-CT (P-CT). METHODS AND MATERIALS: 24 patients (54-79 years) undergoing P-CT before and shortly after DEB-TACE of HCC were prospectively included in this dual-center study. Two readers determined arterial-liver-perfusion (ALP, mL/min/100mL), portal-venous-perfusion (PLP, mL/min/100mL) and the hepatic-perfusion-index (HPI, %) by placing matched regions-of-interests within each HCC before and after DEB-TACE...
June 2017: European Journal of Radiology
https://www.readbyqxmd.com/read/28628947/meta-analysis-of-determinants-of-survival-following-treatment-of-recurrent-hepatocellular-carcinoma
#7
REVIEW
S Erridge, P H Pucher, S R Markar, G Malietzis, T Athanasiou, A Darzi, M H Sodergren, L R Jiao
BACKGROUND: Intrahepatic recurrence of hepatocellular carcinoma (HCC) following resection is common. However, no current consensus guidelines exist to inform management decisions in these patients. Systematic review and meta-analysis of survival following different treatment modalities may allow improved treatment selection. This review aimed to identify the optimum treatment strategies for HCC recurrence. METHODS: A systematic review, up to September 2016, was conducted in accordance with MOOSE guidelines...
June 19, 2017: British Journal of Surgery
https://www.readbyqxmd.com/read/28626733/the-overall-survival-of-patients-with-hepatocellular-carcinoma-correlates-with-the-newly-defined-time-to-progression-after-transarterial-chemoembolization
#8
Tadaaki Arizumi, Kazuomi Ueshima, Mina Iwanishi, Tomohiro Minami, Hirokazu Chishina, Masashi Kono, Masahiro Takita, Norihisa Yada, Satoru Hagiwara, Yasunori Minami, Hiroshi Ida, Yoriaki Komeda, Mamoru Takenaka, Toshiharu Sakurai, Tomohiro Watanabe, Naoshi Nishida, Masatoshi Kudo
AIM/BACKGROUND: The ultimate aim of any treatment for hepatocellular carcinoma (HCC) is to improve overall survival (OS); however, the clinical significance of time to progression (TTP) after transarterial chemoembolization (TACE) is unclear. This retrospective study examined the association between OS and the newly defined time to TACE progression (TTTP) to assess whether TTTP can be an alternative to OS in HCC patients with Barcelona Clinic Liver Cancer (BCLC) stage B. METHODS: Between January 2006 and December 2013, 592 patients with HCC (BCLC B1, n = 118; BCLC B2, n = 170) underwent TACE...
June 2017: Liver Cancer
https://www.readbyqxmd.com/read/28617447/targeting-the-vasculature-in-hepatocellular-carcinoma-treatment-starving-versus-normalizing-blood-supply
#9
Ken Liu, Xiang Zhang, Weiqi Xu, Jinbiao Chen, Jun Yu, Jennifer R Gamble, Geoffrey W McCaughan
Traditional treatments for intermediate or advanced stage hepatocellular carcinoma (HCC) such as transarterial chemoembolization (TACE) and anti-angiogenesis therapies were developed to starve tumor blood supply. A new approach of normalizing structurally and functionally abnormal tumor vasculature is emerging. While TACE improves survival in selected patients, the resulting tumor hypoxia stimulates proliferation, angiogenesis, treatment resistance and metastasis, which limits its overall efficacy. Vessel normalization decreases hypoxia and improves anti-tumor immune infiltrate and drug delivery...
June 15, 2017: Clinical and Translational Gastroenterology
https://www.readbyqxmd.com/read/28611522/radiological-response-and-inflammation-scores-predict-tumour-recurrence-in-patients-treated-with-transarterial-chemoembolization-before-liver-transplantation
#10
Daniele Nicolini, Andrea Agostini, Roberto Montalti, Federico Mocchegiani, Cinzia Mincarelli, Alessandra Mandolesi, Nicola L Robertson, Roberto Candelari, Andrea Giovagnoni, Marco Vivarelli
AIM: To investigate the prognostic value of the radiological response after transarterial chemoembolization (TACE) and inflammatory markers in patients affected by hepatocellular carcinoma (HCC) awaiting liver transplantation (LT). METHODS: We retrospectively evaluated the preoperative predictors of HCC recurrence in 70 patients treated with conventional (n = 16) or doxorubicin-eluting bead TACE (n = 54) before LT. The patient and tumour characteristics, including the static and dynamic alpha-fetoprotein, neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio (PLR) measurements, were recorded...
May 28, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28605745/current-standard-and-future-perspectives-in-non-surgical-therapy-for-hepatocellular-carcinoma
#11
Tobias Eggert, Tim F Greten
BACKGROUND: Hepatocellular carcinoma (HCC) is an aggressive liver tumor with a poor 5-year survival rate. Many HCCs are not amenable to surgical resection, because of tumor size, location, or because of the patient's poor liver function, a common obstacle to HCC therapy, because HCCs almost always develop in chronically inflamed livers. SUMMARY: In recent years, many efforts have been made to improve patient survival by conducting clinical trials investigating local and systemic treatment options for patients with unresectable tumors...
June 13, 2017: Digestion
https://www.readbyqxmd.com/read/28603426/efficacy-and-safety-of-tace-in-combination-with-sorafenib-for-the-treatment-of-tace-refractory-advanced-hepatocellular-carcinoma-in-chinese-patients-a-retrospective-study
#12
Jianbing Wu, An Li, Jiajin Yang, Yanjun Lu, Jie Li
BACKGROUND: Transarterial chemoembolization (TACE) and sorafenib (SOR) are well-established treatments for hepatocellular carcinoma (HCC). This study evaluates the efficacy and safety of SOR combined with TACE in the treatment of patients with TACE-refractory, advanced-stage HCC. METHODS: This retrospective study included 61 patients with TACE-refractory advanced HCC. Patients were divided into TACE + SOR (n=30) and TACE (n=31) treatment groups. Patient demographic and clinical characteristics, overall survival (OS), time to progression (TTP), disease control rate (DCR), and adverse events (AEs) were compared between the two groups...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28602057/body-composition-predicts-survival-in-patients-with-hepatocellular-carcinoma-treated-with-transarterial-chemoembolization
#13
Neehar D Parikh, Peng Zhang, Amit G Singal, Brian A Derstine, Venkat Krishnamurthy, Pranab Barman, Akbar K Waljee, Grace L Su
Purpose: The prognosis of patients with hepatocellular carcinoma (HCC) undergoing transarterial chemoembolization (TACE) is often uncertain. We aimed to utilize analytic morphomics, a high-throughput imaging analysis, to assess if body composition is predictive of post-TACE survival. Materials and Methods: We included patients from a single center (Ann Arbor VA) who had TACE as the primary treatment for HCC and had a pre-treatment CT scans. Univariate analysis and multivariate conditional inference tree analysis were utilized to identify the morphomic characteristics predictive of one-year survival...
June 1, 2017: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://www.readbyqxmd.com/read/28600578/transarterial-infusion-chemotherapy-with-and-without-embolisation-in-hepatocellular-carcinoma-patients-a-systematic-review-and-meta-analysis
#14
Jing Zhao, Dapeng Li, Yue Shi, Fengling Shi, Chengting Feng, Wei Li, Min Tao, Rongrui Liang
INTRODUCTION: The purpose of this meta-analysis was to compare the efficacy of transarterial chemoembolisation (TACE) and iodised oil infusion chemotherapy without embolisation (TAI) in patients with hepatocellular carcinoma. MATERIALS AND METHODS: We searched for randomised controlled trials, retrospective cohort studies, and two-arm prospective studies that compared the clinical outcomes in patients who received TACE and TAI treatment. Database search was performed through 14 December 2016...
May 2017: Annals of the Academy of Medicine, Singapore
https://www.readbyqxmd.com/read/28593432/risk-of-acute-kidney-injury-after-transarterial-chemoembolisation-in-hepatocellular-carcinoma-patients-a-nationwide-population-based-cohort-study
#15
Bo-Ching Lee, Kao-Lang Liu, Cheng-Li Lin, Chia-Hung Kao
OBJECTIVE: This nationwide population-based cohort study evaluated the association between acute kidney injury (AKI) and transarterial chemoembolisation (TACE) in patients with hepatocellular carcinoma (HCC). METHODS: The case cohort included patients with HCC who had undergone TACE treatment between 1 January 1998 and 31 March 2010. Patients with baseline chronic kidney disease, with baseline end-stage renal disease, and aged younger than 20 years were excluded...
June 7, 2017: European Radiology
https://www.readbyqxmd.com/read/28589145/metastasis-associated-protein-1-is-involved-in-angiogenesis-after-transarterial-chemoembolization-treatment
#16
Tao Xue, Wenming Feng, Hongbin Yu, Ming Zhu, Maoyun Fei, Ying Bao, Xiaoyi Wang, Wenxue Ma, Guiyuan Lv, Jianming Guan, Suhong Chen
BACKGROUND: Transarterial chemoembolization (TACE), a well-established treatment for unresectable hepatocellular carcinoma (HCC), blocks the arterial blood supply to the tumor, which can be short-lived as development of collateral neovessels, leading to the failure of treatment. Metastasis-associated protein 1 (MTA1) is involved in development of tumors and metastases. However, the role of MTA1 in angiogenesis is still obscure. METHODS: We detected the expression of MTA1 and hypoxia-inducible factor-1α (HIF-1α) and microvessel density (MVD) value in liver tumor tissues and tumor periphery before and after TACE treatment...
2017: BioMed Research International
https://www.readbyqxmd.com/read/28588794/intrahepatic-biloma-following-transcatheter-arterial-chemoembolization-for-hepatocellular-carcinoma-incidence-imaging-features-and-management
#17
Bo Zhang, Yongjian Guo, Ketong Wu, Hong Shan
Repeat transcatheter arterial chemoembolization (TACE) becomes more challenging for patients with intrahepatic biloma following TACE for hepatocellular carcinoma (HCC). The purpose of this study was to investigate the clinical course, incidence, imaging features and outcome and to explore the reasonable therapy scheme for intrahepatic biloma following TACE for HCC.A total of 4,695 TACE procedures were performed for 1,923 patients with HCC. Twenty patients with intrahepatic biloma following TACE were studied retrospectively...
June 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28583650/early-response-evaluation-using-ct-perfusion-one-day-after-transarterial-chemoembolization-for-hcc-predicts-treatment-response-and-long-term-disease-control
#18
Dietmar Tamandl, Fredrik Waneck, Wolfgang Sieghart, Sylvia Unterhumer, Claus Kölblinger, Pascal Baltzer, Ahmed Ba-Ssalamah, Christian Loewe
PURPOSE: To determine the value of CT perfusion (CTP) for early response assessment after transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). MATERIALS AND METHODS: Between April 2013 and April 2015, 41 HCC (16 patients) were included in this study. CT perfusion was performed before and one day after TACE. Blood flow (BF), blood volume (BV), time to start (TTS), arterial liver perfusion (ALP), portal liver perfusion (PVP) and hepatic perfusion index (HPI) were measured...
May 2017: European Journal of Radiology
https://www.readbyqxmd.com/read/28582848/curative-effect-of-transcatheter-arterial-chemoembolization-combined-with-radiofrequency-ablation-in-treating-hepatic-cell-carcinoma-and-its-effect-on-serum-markers
#19
Fu-Qiang Jiang, Wei Lu, Chao Yang, Peng Du, Jun-Peng Ma, Jian Yang, Peng Xie, Zhe Zhang
BACKGROUND: Hepatic cell carcinoma (HCC) is more common in clinical practice, and has high malignant degree. OBJECTIVE: This study aims to analyze the curative effect of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation (RFA) in treating hepatic cell carcinoma (HCC) and its effect on serum markers. METHODS: A total of 106 cases of patients with hepatic cell carcinoma treated in our hospital were randomly divided into two groups: observation group and control group...
May 26, 2017: Cancer Biomarkers: Section A of Disease Markers
https://www.readbyqxmd.com/read/28581250/new-intermediate-stage-subclassification-for-patients-with-hepatocellular-carcinoma-treated-with-transarterial-chemoembolization
#20
Jin Hyoung Kim, Ju Hyun Shim, Han Chu Lee, Kyu-Bo Sung, Heung-Kyu Ko, Gi-Young Ko, Dong Il Gwon, Jong Woo Kim, Young-Suk Lim, Seong Ho Park
AIM: The need for a subclassification of Barcelona Clinic Liver Cancer (BCLC) intermediate-stage (BCLC B) has arisen because of its diversity. We evaluated the prognostic capability of the BCLC B subclassification proposed by Bolondi et al. in patients treated with transarterial chemoembolization (TACE). Furthermore, we introduce a new subclassification for intermediate-stage hepatocellular carcinoma (HCC) by using a new parameter related to tumor burden (up-to-11 criteria). METHODS: Of 3268 patients treated with TACE as first-line treatment, 821 patients with intermediate-stage HCC were included in this study...
June 5, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
keyword
keyword
8327
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"